Not medical advice. HGH Fragment 176-191 is a research compound. This guide does not provide dosing, diagnosis, therapy recommendations, or claims about effects in humans.
HGH Fragment 176-191 is the synthetic C-terminal tail of growth hormone that captures the lipolytic (fat-burning) activity of the parent molecule without the growth or insulin effects.
One-paragraph overview from our research datasheet — still scientific, but faster to read than the full mechanism list below.
HGH Fragment 176-191, C-terminal lipolytic domain of human growth hormone activating β3-adrenergic receptor-mediated lipolysis without IGF-1 effects.
Peer-reviewed literature typically discusses HGH Fragment 176-191 in specific experimental settings. The points below reflect how the scientific community frames this compound—not as health claims, but as the research questions being asked.
Research vs. personal use: Literature describes experiments in controlled lab and animal models. This is distinct from any real-world use; our products are for laboratory research only.
Growth-hormone axis peptides are researched for how they signal through the GH/IGF pathway in animals and cells. Studies focus on endocrine biology and metabolism, not on prescribing or outcomes in people.
Our datasheet lists mechanistic themes observed in preclinical work. These are research endpoints, not health claims. They help scientists understand and compare pathways.
Storage requirements: Lyophilised powder: store in freezer (−20 °C). Reconstituted: refrigerate 1–6 °C, away from sunlight. Use within the validated stability window for the specific batch and formulation. · Learn best practices in our detailed storage guide.
Research dosing context: Literature typically discusses 250–500 mcg subcutaneously · 1–2 times daily on empty stomach · Serum t½ ≈ 4 min (rapid amino-terminal truncation cascade); metabolic effects persist significantly beyond circulating peptide clearance; approximately 40% oral bioavailability demonstrated in animal models for related AOD-9604 variant. Administer fasted for optimal lipolytic signaling, insulin antagonizes cAMP/PKA activation.
Preparation steps: Follow our detailed reconstitution guide, use the calculator tool for volume confirmation, and always verify purity with the COA reading guide.
HGH Fragment 176-191 is a synthetic peptide corresponding to the C-terminal region (amino acids 176-191) of human growth hormone — the part that carries HGH's fat-metabolising (lipolytic) activity. It is studied for fat metabolism without the growth or IGF-1 effects of the full hormone. Supplied as a lyophilised research-grade powder for laboratory use only.
In the research literature HGH Fragment 176-191 is used as a tool compound to study lipolysis and fat metabolism — it is the lipolytic domain of HGH isolated from the growth-promoting domains. New-U supplies it strictly for in-vitro and animal-model research; it is not for human use.
HGH Fragment 176-191 is not a scheduled or controlled substance in most jurisdictions and can be sold and purchased as a research chemical for laboratory use. It is not an approved medicine, and it is on the WADA Prohibited List for competing athletes. Buyers are responsible for compliance with their local laws; New-U supplies it for research use only.
AOD-9604 is the same C-terminal lipolytic fragment with an N-terminal tyrosine added to the front for improved stability. The two share essentially the same β3-adrenergic / lipolysis mechanism, but AOD-9604 is the version that was actually carried through pharmaceutical development (multiple human clinical trials, including a Phase 2b obesity study), whereas the plain 176-191 fragment has little human research of its own. Both remain research tools.
They work through completely different mechanisms. HGH Fragment 176-191 is a lipolytic peptide - it acts directly on fat cells via the β3-adrenergic pathway to mobilise stored triglycerides, without touching appetite. GLP-1 receptor agonists such as semaglutide instead reduce food intake through appetite and satiety signalling. The fragment is studied as a tool for fat-metabolism mechanisms, not as an appetite agent, and is supplied for laboratory research only.
No. That is the whole point of isolating this fragment - it does not bind the growth hormone receptor, so it does not trigger hepatic IGF-1 synthesis and does not produce the counter-regulatory insulin-opposing effects of full-length HGH. Preclinical and early clinical data are consistent on this.
Because insulin antagonises the cAMP/PKA signal that the fragment is trying to amplify. If you dose in a fed state with elevated insulin, the lipolytic signal is blunted. Research protocols typically use an empty-stomach or pre-cardio window.
Keep the lyophilised powder frozen at −20 °C. After reconstitution with bacteriostatic water, refrigerate at 1-6 °C and protect from light. The cyclic disulfide is relatively stable but the peptide itself is short-lived in solution, so plan your dosing window accordingly.
No, and no. This article is educational only. We do not provide dosing, medical recommendations, or health claims. Our products are sold strictly for laboratory research, not for personal use of any kind.
Open the shop listing via “View product details.” There you will see batch specs, the Certificate of Analysis (COA), concentration, purity grade, and available SKUs with current pricing.
Other compounds researchers often read about alongside HGH Fragment 176-191.
Primary literature and registries for HGH Fragment 176-191, plus mainstream coverage of the peptide category. Research use only - not medical advice.
Databases & literature:
Peptides in the news:
Access concentration, batch info, variants, and current pricing on our shop.
Also known as: HGH Frag 176-191, AOD-9604 Precursor, GH Fragment, C-Terminal HGH Fragment, Lipolytic Fragment, Fat Loss Fragment, Tyr-hGH177-191